Sanofi acquires Provention Bio for $2.9 billion to boost its diabetes portfolio
Sanofi acquires Provention Bio, and its TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D).
Drugs
Medical
Pharma